6 374 $2.20 drop after 9 months

ExpiredNutraviva PET Advanced Mobility Formula for Dogs

$45.45 ~~$52.95~~ Save 14% ($7.50)

Posted 23 April 2024 5:16:21 am

Check current price @ Aussie Health Products. Seen for $49.90 yesterday.

Deal history

Expired $2.20 drop after 9 months 23 April 2024: $45.45
Expired $1.30 drop after 23 days 27 July 2023: $47.65
Expired 04 July 2023: $48.95

Price history

Description

Joint degeneration begins at a relatively early age for all canines. Arthritis and hip dysplasia are reported to affect approximately 80% of all senior dogs. Nutraviva's Advanced Mobility Formula for Dogs is a premium collagen based supplement with APVMA approval. It is fortified with glucosamine, chondroitin, MSM, hyaluronic acid and vitamin C specifically designed for your dog. Nutraviva's Advanced Mobility Formula for Dogs is a registered complementary food supplement suitable for all dog breeds and sizes and is designed to be taken daily as long term use may help improve joint health and functioning.

Ingredients:
Active constituents: 649mg glucosamine sulfate (sourced from chitin - shellfish) 260 mg chondroitin sulfate (sourced from bovine cartilage)

Collagen: Helps to reduce the breakdown of collagen fibres within the bones, joints and connective as your pet's age.

Glucosamine: Is a natural anti-inflammatory and plays a vital role in building and maintaining healthy joints.

Chondroitin: Helps to maintain cartilage and promotes joint lubrication which assists with shock absorption and reduced friction.

Hyaluronic acid: Increase the viscosity of synovial fluid within joints, further reducing friction and increasing cushioning of the joint capsule.

MSM: Improves joint flexibility and reduces pain and inflammation.

Vitamin C: Plays a critical role in assisting with collagen formation.

Share this deal

No comments yet, be the first to add one.

Post a new comment as anonymous, or sign-in to your account:

When you click on a link or place an order, RewardBargain may receive a commission, however, this does not influence in any way the decision to publish deals.